title: Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis.
abstract: The Global Program to Eliminate Lymphatic Filariasis (LF) has a target date of 2020. This program is progressing well in many countries. However, progress has been slow in some countries, and others have not yet started their mass drug administration (MDA) programs. Acceleration is needed. We studied how increasing MDA frequency from once to twice per year would affect program duration and costs by using computer simulation modeling and cost projections. We used the LYMFASIM simulation model to estimate how many annual or semiannual MDA rounds would be required to eliminate LF for Indian and West African scenarios with varied pre-control endemicity and coverage levels. Results were used to estimate total program costs assuming a target population of 100,000 eligibles, a 3% discount rate, and not counting the costs of donated drugs. A sensitivity analysis was done to investigate the robustness of these results with varied assumptions for key parameters. Model predictions suggested that semiannual MDA will require the same number of MDA rounds to achieve LF elimination as annual MDA in most scenarios. Thus semiannual MDA programs should achieve this goal in half of the time required for annual programs. Due to efficiency gains, total program costs for semiannual MDA programs are projected to be lower than those for annual MDA programs in most scenarios. A sensitivity analysis showed that this conclusion is robust. Semiannual MDA is likely to shorten the time and lower the cost required for LF elimination in countries where it can be implemented. This strategy may improve prospects for global elimination of LF by the target year 2020.
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. w.stolk@erasmusmc.nl
authors.forename: Wilma A
authors.initials: WA
authors.lastname: Stolk
authors.forename: Quirine A
authors.initials: QA
authors.lastname: ten Bosch
authors.forename: Sake J
authors.initials: SJ
authors.lastname: de Vlas
authors.forename: Peter U
authors.initials: PU
authors.lastname: Fischer
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Weil
authors.forename: Ann S
authors.initials: AS
authors.lastname: Goldman
mesh_terms: D003198:Computer Simulation; D003365:Costs and Cost Analysis; D004358:Drug Therapy / Q000191:economics* / Q000379:methods*; D004605:Elephantiasis, Filarial / Q000188:drug therapy*; D005260:Female; D005369:Filaricides / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D005369:Filaricides